Search by drug, manufacturer, or indication

Displaying 931 - 940 of 1165

Giotrif (afatinib)

Status:

Concluded with an LOI

Manufacturer:

Boehringer Ingelheim (Canada) Ltd.

Indication:

Advanced Non-Small Cell Lung Cancer

Last updated November 23, 2017

Metoject (methotrexate)

Status:

Concluded with an LOI

Manufacturer:

Medexus Pharmaceuticals, Inc.

Indication:

Rheumatic Conditions

Last updated November 20, 2017

Pheburane (sodium phenylbutyrate)

Status:

Concluded with an LOI

Manufacturer:

M�dunik Canada Inc.

Indication:

Urea cycle disorders

Last updated November 20, 2017

Opdivo (nivolumab)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Head and Neck Squamous Cell Carcinoma (HNSCC)

Last updated November 20, 2017

Stivarga (regorafenib)

Status:

Concluded with an LOI

Manufacturer:

Bayer Inc.

Indication:

Gastrointestinal Stromal Tumours

Last updated November 9, 2017

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Non-small Cell Lung Cancer

Last updated November 1, 2017

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Non-small Cell Lung Cancer

Last updated November 1, 2017

Kevzara (sarilumab)

Status:

Concluded without agreement

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Rheumatoid Arthritis

Last updated October 26, 2017

Kalydeco (ivacaftor)

Status:

Concluded without agreement

Manufacturer:

Vertex Pharmaceuticals (Canada) Incorporated

Indication:

Cystic Fibrosis (CFTR gating mutations)

Last updated October 24, 2017

Repatha (evolocumab)

Status:

Concluded with an LOI

Manufacturer:

Amgen Canada Inc.

Indication:

Primary hyperlipidemia and mixed dyslipidemia

Last updated October 23, 2017